Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Brooks

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Immunotherapy|May 2, 2024
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summaryEmma Guttman-Yassky, Lila Bahadori, Laura Brooks, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studiesGerard J Criner, Bartolome R Celli, Dave Singh, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|December 21, 2019
Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthmaArnaud Bourdin, Dominick Shaw, Andrew Menzies-Gow, et al.
Immunotherapy|March 31, 2025
Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO studySabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
The British Journal of Dermatology|February 17, 2024
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trialSabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
The New England Journal of Medicine|June 26, 2024
Eosinophil Depletion with Benralizumab for Eosinophilic EsophagitisMarc E Rothenberg, Evan S Dellon, Margaret H Collins, et al.
Pediatrics|April 9, 2026
Defining the Practice of the General Pediatrician: Entrustable Professional Activities UpdateMeghan O'Connor, Laura Chiel, Joanna Lewis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2022
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastomaMatt Lechner, Yoko Takahashi, Mario Turri-Zanoni, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Immunotherapy|May 2, 2024
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summaryEmma Guttman-Yassky, Lila Bahadori, Laura Brooks, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studiesGerard J Criner, Bartolome R Celli, Dave Singh, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|December 21, 2019
Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthmaArnaud Bourdin, Dominick Shaw, Andrew Menzies-Gow, et al.
Immunotherapy|March 31, 2025
Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO studySabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
The British Journal of Dermatology|February 17, 2024
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trialSabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, et al.
The New England Journal of Medicine|June 26, 2024
Eosinophil Depletion with Benralizumab for Eosinophilic EsophagitisMarc E Rothenberg, Evan S Dellon, Margaret H Collins, et al.
Pediatrics|April 9, 2026
Defining the Practice of the General Pediatrician: Entrustable Professional Activities UpdateMeghan O'Connor, Laura Chiel, Joanna Lewis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2022
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastomaMatt Lechner, Yoko Takahashi, Mario Turri-Zanoni, et al.
Pageof 4